Return to homepagePandemic Pact

Targeting SARS-CoV-2 using Stealth nanoparticles loaded with gene silencing siRNAs

  • Funded by National Health and Medical Research Council (NHMRC)
  • Total publications:0 publications

Grant number: GA85469

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2021

  • Known Financial Commitments (USD)

    $219,208.86

  • Funder

    National Health and Medical Research Council (NHMRC)

  • Principal Investigator

    N/A

  • Research Location

    Australia

  • Lead Research Institution

    Griffith University

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

We have developed technology that turns off respiratory virus genes, resulting in a 99.9 percent reduction in virus growth in animal models. We have already used it against Hendravirus, RSV, and hMPV. These stealth nanoparticles, made from FDA approved materials, are able to deliver to the infected lung cells via the blood stream, bypassing the inflamed airway that blocks other medicines from working. Here we will explore this for COVD19 virus.